Original Articles
8 May 2025
Early Access
A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
154
Views
42
Downloads
Authors
Objective. Limited data in Latin America exists regarding the efficacy of switches from original biologicals to biosimilars in real-life scenarios. Currently, no studies assess this switch using imaging. The objective of this study was to evaluate clinical, functional, ultrasonographic, and radiological responses in a group of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) switched from original adalimumab (oADA) to biosimilar (bADA) (GP2017).
Methods. A prospective cohort study included diagnosed RA and PsA patients undergoing oADA treatment. At the baseline visit, blood analysis, X-rays, ultrasound, and an interview for sociodemographic and clinical data were conducted. Evaluators were unaware of each other's data. Patients switched to bADA during follow-up and were assessed in the same program within 3 to 12 months post-switch (only including patients with all evaluations).
Results. Out of 270 RA cohort patients, 35 met the criteria for complete pre-and-post control post-switch to bADA (GP2017), along with 15 PsA patients. The mean time between the switch and the second evaluation was 4.1 months (interquartile range 7). No statistical differences were observed in disease activity or functional capacity. Regarding imaging, no difference was found in X-ray erosion number; however, ultrasonography revealed decreased power Doppler (PD) activity, but not grayscale findings. No differences in acute phase reactants, joint count, or patient visual analog scale were observed between controls.
Conclusions. In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
Altmetrics
Downloads
Download data is not yet available.
Citations
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA 2018; 320: 1360-72. DOI: https://doi.org/10.1001/jama.2018.13103
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-70. DOI: https://doi.org/10.1056/NEJMra1505557
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509. DOI: https://doi.org/10.1136/annrheumdis-2013-204573
Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm 2019; 15: 310-7. DOI: https://doi.org/10.1016/j.sapharm.2018.05.009
Heo YA. GP2017: an adalimumab biosimilar. BioDrugs 2018; 32: 635-8. DOI: https://doi.org/10.1007/s40259-018-0318-x
Carstensen SMD, Terslev L, Jensen MP, Østergaard M. Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis. Curr Opin Rheumatol 2020; 32: 264-72. DOI: https://doi.org/10.1097/BOR.0000000000000709
Ruta S, Prado ES, Chichande JT, Ruta A, Salvatori F, Magri S, et al. EULAR definition of “arthralgia suspicious for progression to rheumatoid arthritis” in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. Clin Rheumatol 2020; 39: 1493-9. DOI: https://doi.org/10.1007/s10067-019-04855-0
Garcia-Salinas R, Magri S, Mareco J, Jaldin R, Perez R, Ruta S, et al. Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors. Rheumatology 2024; keae562. DOI: https://doi.org/10.1093/rheumatology/keae562
Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA et al (2004) Validation and crosscultural adaptation of an Argentine Spanish version of the Health Assessment Questionnaire disability index. J Clin Rheumatol 10(3):110–115 DOI: https://doi.org/10.1097/01.rhu.0000128732.58292.cd
Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60: 641-9. DOI: https://doi.org/10.1136/ard.60.7.641
Wakefield RJ, Balint P V, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485-7.
Gutierrez M, Filippucci E, Salaffi F, Di Geso L, Grassi W. Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level. Ann Rheum Dis 2011; 70: 1111-4. DOI: https://doi.org/10.1136/ard.2010.147272
Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005; 64: 375-81. DOI: https://doi.org/10.1136/ard.2004.023929
Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. Ultrasonographic assessment of inflammatory activity in rheumatoid arthritis: comparison of extended versus reduced joint evaluation. Clin Exp Rheumatol 2005; 23: 881-4.
Kozlowski S, Woodcock J, Midthun K, Behrman Sherman R. Developing the nation’s biosimilars program. N Engl J Med 2011; 365: 385-8. DOI: https://doi.org/10.1056/NEJMp1107285
Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-2. DOI: https://doi.org/10.1038/nbt.1839
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019; 78: 192-200. DOI: https://doi.org/10.1136/annrheumdis-2018-213474
Norman P. Humira® : recent developments. Pharm Pat Anal 2017; 6: 89-90. DOI: https://doi.org/10.4155/ppa-2017-0012
Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep 2018; 20: 57. DOI: https://doi.org/10.1007/s11926-018-0769-6
Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. BioDrugs 2020; 34: 809-23. DOI: https://doi.org/10.1007/s40259-020-00447-6
Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol 2018; 179: 623-31. DOI: https://doi.org/10.1111/bjd.16890
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304-16. DOI: https://doi.org/10.1016/S0140-6736(17)30068-5
Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep 2017; 19: 37. DOI: https://doi.org/10.1007/s11926-017-0658-4
McKinnon RA, Cook M, Liauw W, Marabani M, Marschner IC, Packer NH, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs 2018; 32: 27-52. DOI: https://doi.org/10.1007/s40259-017-0256-z
Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med 2020; 180: 902-3. DOI: https://doi.org/10.1001/jamainternmed.2020.0338
Nabi H, Georgiadis S, Loft AG, Hendricks O, Andersen M, Chrysidis S, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis 2021; 80: 1400-9. DOI: https://doi.org/10.1136/annrheumdis-2021-219951
Azevedo VF, Babini A, Caballero-Uribe CV, Castañeda-Hernández G, Borlenghi C, Jones HE. Practical guidance on biosimilars, with a focus on Latin America. J Clin Rheumatol 2019; 25: 91-100. DOI: https://doi.org/10.1097/RHU.0000000000000881
Kowalski SC, Benavides JA, Roa PAB, Galarza-Maldonado C, Caballero-Uribe CV, Soriano ER, et al. PANLAR consensus statement on biosimilars. Clin Rheumatol 2019; 38: 1485-96. DOI: https://doi.org/10.1007/s10067-019-04496-3
García Salinas R, Ruta S, Chichande JT, Prado ES, Ruta A, Salvatori F, et al. “Reuma-Check”: performance of a comprehensive fast-track program for the diagnosis of axial spondyloarthritis in South America. J Clin Rheumatol 2021; 27: 175-81. DOI: https://doi.org/10.1097/RHU.0000000000001654
How to Cite
A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1748
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
